LABELS · e4a8e5b4-af77-4eca-92de-cd0982969b82

Medrol

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-11-14
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Full extracted label fields

application numbers

NDA011153

boxed warning exact

brand names

Medrol

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39d5270b-d957-4821-93d6-501b7b9f02d4

generic names

METHYLPREDNISOLONE

e4a8e5b4-af77-4eca-92de-cd0982969b82

indications and usage exact

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

indications and usage tables exact

is original packager

true

manufacturer names

Pharmacia & Upjohn Company LLC

matched search terms

cancer
lymphomas
leukemia

package ndcs

0009-0049-02
0009-0056-02
0009-0056-04
0009-0022-01
0009-0073-01
0009-0176-01
0009-0020-01

product ndcs

0009-0020
0009-0049
0009-0056
0009-0022
0009-0073
0009-0176

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

197969
197971
197973
207136
207137
207138
207141
259966
260330
328161
762675
834023

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

NDA011153

brand names

Medrol

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 282
end exclusive: true
exact text: INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where appl
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 0

current approval status

not_reconciled

duplicate text group

dup-16fcaa1655e4ffdba705

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-0c86d6fc6d6d1a47478f

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

end: 50
end exclusive: true
exact text: are indicated
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 37

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 82
end exclusive: true
exact text: INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 564
end exclusive: true
exact text: INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 0

current approval status

not_reconciled

duplicate text group

dup-f25288f81829d428bdf6

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-b2425728c46d74249f50

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 364
end exclusive: true
exact text: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 83

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 662
end exclusive: true
exact text: one or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 165

current approval status

not_reconciled

duplicate text group

dup-ead326c13591eaa42f2e

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-01de722e8cf35acb77b9

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 462
end exclusive: true
exact text: Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 365

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1118
end exclusive: true
exact text: rticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 263

current approval status

not_reconciled

duplicate text group

dup-679fbcd5d756d70806c1

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-187d0421dd13e802de2d

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 918
end exclusive: true
exact text: Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 463

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1304
end exclusive: true
exact text: Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe pso
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 719

current approval status

not_reconciled

duplicate text group

dup-0a0c0b141920bc9af33e

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-c5984c5c2b935a0fb78a

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1104
end exclusive: true
exact text: Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 919

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1513
end exclusive: true
exact text: arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactio
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 905

current approval status

not_reconciled

duplicate text group

dup-e0c0bccb820564c59fc3

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-6271fc23a2f8ee0b88e6

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1313
end exclusive: true
exact text: Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 1105

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1787
end exclusive: true
exact text: gic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 1114

current approval status

not_reconciled

duplicate text group

dup-77a7a02650a1eea8cc22

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-9290a1b7ddefefadff91

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1587
end exclusive: true
exact text: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 1314

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2158
end exclusive: true
exact text: tractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate a
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 1388

current approval status

not_reconciled

duplicate text group

dup-d91a8639f62d805200d3

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-15ab9397c18d08002408

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1958
end exclusive: true
exact text: Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 1588

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2411
end exclusive: true
exact text: phthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid)
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 1759

current approval status

not_reconciled

duplicate text group

dup-c25b9ec61bd5d1d0427e

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-85fa7a7b7ca494148c6f

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2211
end exclusive: true
exact text: Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 1959

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2632
end exclusive: true
exact text: sis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2012

current approval status

not_reconciled

duplicate text group

dup-b29ddecd8c79586372b8

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-1f97a27652d4b3b4c480

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

context exact
ematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune)
kind
age
polarity
not_inferred
span
end
2279
end exclusive
true
exact text
adults
label id
e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start
2273
context exact
bocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (
kind
age
polarity
not_inferred
span
end
2316
end exclusive
true
exact text
adults
label id
e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start
2310

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2432
end exclusive: true
exact text: Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2212

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2748
end exclusive: true
exact text: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases T
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2233

current approval status

not_reconciled

duplicate text group

dup-fc2417e7fd32949aca13

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-828968e00fb5d7ed7cd2

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

context exact
es For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.
kind
age
polarity
not_inferred
span
end
2516
end exclusive
true
exact text
adults
label id
e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start
2510

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2548
end exclusive: true
exact text: Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2433

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2920
end exclusive: true
exact text: anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscella
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2349

current approval status

not_reconciled

duplicate text group

dup-b59784a75bb8959ce32a

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-2d4ae26d0f841a9fd0ea

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2720
end exclusive: true
exact text: Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2549

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3050
end exclusive: true
exact text: e leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous ch
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2521

current approval status

not_reconciled

duplicate text group

dup-e68fa7fbf21f0a15f188

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-d6e25bc05d7f09615a8f

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2850
end exclusive: true
exact text: Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2721

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3111
end exclusive: true
exact text: remia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involve
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2651

current approval status

not_reconciled

duplicate text group

dup-99e3cbcf8877c47dea9f

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-22dec3532583260ed298

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2911
end exclusive: true
exact text: Nervous System Acute exacerbations of multiple sclerosis 13.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2851

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 15 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3116
end exclusive: true
exact text: sus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2712

current approval status

not_reconciled

duplicate text group

dup-9c34b26b7dfd4ea25f14

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-34f3273b1ae94f1ad929

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3061
end exclusive: true
exact text: Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2912

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 16 · unclassified context

application numbers

NDA011153

brand names

Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3116
end exclusive: true
exact text: tem Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 2862

current approval status

not_reconciled

duplicate text group

dup-b25a328856c26bc28e02

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-1917f54c7484df229d9a

label id

e4a8e5b4-af77-4eca-92de-cd0982969b82

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3116
end exclusive: true
exact text: Trichinosis with neurologic or myocardial involvement.
label id: e4a8e5b4-af77-4eca-92de-cd0982969b82
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c573dae6001e76b69e5f220c6c63d773da35dc743c564c184e94a81a114c336e
start: 3062

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e4a8e5b4-af77-4eca-92de-cd0982969b82%22

spl effective date

2025-11-14

spl set id

39d5270b-d957-4821-93d6-501b7b9f02d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice